Entity

Time filter

Source Type

San Sebastián de los Reyes, Spain

Diaz-Diaz R.M.,Hospital Universitario Infanta Sofia
Actas Dermo-Sifiliograficas | Year: 2014

We review advertisements published in the journal . Actas Dermosifiliográficas between 1909 and 1939. Treatments for sexually transmitted diseases were advertised with particular frequency, and they offer a case in point that exemplifies the close relationship between the pharmaceutical industry and medical journals. Aportamos algunos datos acerca de los anuncios publicados en la revista . Actas Dermosifiliográficas durante el periodo 1909-1939. Destacan los anuncios relacionados con el tratamiento de las enfermedades de transmisión sexual. Son un ejemplo de la estrecha relación existente entre la industria farmacéutica y las revistas médicas. © 2012 Elsevier España, S.L. and AEDV. Source


Becerra J.L.,Servicio de Neurologia | Ojeda J.,Hospital Universitario Infanta Sofia | Corredera E.,Hospital Clinico Universitario Of Santiago Of Compostela | Gimenez J.R.,Servicio de Neurologia
CNS Drugs | Year: 2012

Epilepsy is one of the most common serious neurological conditions worldwide, with an age-adjusted incidence of approximately 50 per 100 000 persons per year in developed countries. Antiepileptic therapy can result in long-term remission in 60-70% of patients, but many patients will require combination treatment to achieve optimal seizure control, as monotherapy is ineffective at controlling seizures in 30-53% of patients. Despite the increase in available treatment options, patient outcomes have not improved significantly and there is still a need for more effective therapies. Drugs used in the treatment of focal-onset seizures are a diverse range of compounds, and in most cases their mechanism of action is unknown or poorly defined. This review discusses the efficacy and safety of the newer adjuvant antiepileptic therapies that may improve outcomes in patients unresponsive to monotherapy, including clobazam, vigabatrin, lamotrigine, gabapentin, topiramate, tiagabine, levetiracetam, oxcarbazepine, pregabalin, zonisamide and eslicarbazepine, with focus on lacosamide. Lacosamide has been shown to exert its anticonvulsant effects predominantly by enhancement of the slow inactivation of voltage-gated sodium channels. Lacosamide is indicated for use as adjuvant treatment of focal-onset seizures in patients with epilepsy, and there is some evidence that it may also be of use in patients with status epilepticus and cancer patients with epilepsy. The efficacy of lacosamide has been assessed in three randomized, double-blind, placebo-controlled clinical trials, all of which have shown lacosamide to be effective at reducing seizure frequency and increasing 50% responder rates in patients with focal-onset seizures. Long-term lacosamide treatment is generally well tolerated and is not associated with significant drug interactions; the availability of an intravenous form of the drug also makes it particularly useful for a broad range of patients. © 2011 Adis Data Information BV. All rights reserved. Source


Silva-Fernandez L.,Hospital Universitario Of Guadalajara | Loza E.,Institute for Musculoskeletal Health | Martinez-Taboada V.M.,University of Cantabria | Blanco R.,University of Cantabria | And 3 more authors.
Seminars in Arthritis and Rheumatism | Year: 2014

Objective: Relapses and failure are frequent in systemic vasculitis (SV) patients. Biological agents have been prescribed as rescue therapies. The aim of this systematic review is to analyze the current evidence on the therapeutic use of biological agents for SV. Methods: MEDLINE, EMBASE, the Cochrane Database of Systematic Reviews, and the Cochrane Central Register of Controlled Trials were searched up to the end of April 2013. Systematic reviews and meta-analysis, clinical trials, cohort studies, and case series with >3 patients were included. Independent article review and study quality assessment was done by 2 investigators with consensus resolution of discrepancies. Results: Of 3447 citations, abstracts, and hand-searched studies screened, 90 were included. Most of the studies included ANCA-associated vasculitis (AAV) patients and only a few included large vessel vasculitis (LVV) patients. Rituximab was the most used agent, having demonstrated efficacy for remission induction in patients with AAV. A number of studies used different anti-TNFα agents with contrasting results. A few uncontrolled studies on the use of abatacept, alemtuzumab, mepolizumab, and tocilizumab were found. Conclusion: Current evidence on the use of biological therapies for SV is mainly based on uncontrolled, observational data. Rituximab is not inferior to cyclophosphamide for remission induction in AAV and might be superior in relapsing disease. Infliximab and adalimumab are effective as steroid-sparing agents. Etanercept is not effective to maintain remission in patients with granulomatosis with polyangiitis, and serious adverse events have been reported. For LVV, both infliximab and etanercept had a role as steroid-sparing agents, and tocilizumab might be effective also for remission induction in LVV. © 2014 Elsevier Inc. Source


Gutierrez-Gutierrez G.,Hospital Universitario Infanta Sofia
Medicine (Spain) | Year: 2015

Polyneuropathies (PNP) affect 2-8% of the population, have numerous causes and not all can be treated. When studying a PNP, it is advisable to start by classifying the PNP into patterns, each with a reduced differential diagnosis. To this end, we must properly define the PNP through the assessment of a series of clinical characteristics that can be determined through a proper review of the case history and a careful examination. Neurophysiological studies are also essential for classifying the PNP into demyelinating or axonal and determining the predominant type of affected fibers. Lastly, certain additional tests (from blood tests to genetic studies) will provide the definitive diagnosis. Source


Diaz-Diaz R.M.,Hospital Universitario Infanta Sofia
Actas Dermo-Sifiliograficas | Year: 2014

We review advertisements published in the journal Actas Dermosifiliográficas between 1909 and 1939. Treatments for sexually transmitted diseases were advertised with particular frequency, and they offer a case in point that exemplifies the close relationship between the pharmaceutical industry and medical journals. © 2012 Elsevier España, S.L. and AEDV. All rights reserved. Source

Discover hidden collaborations